Modernizing process validation | FSP outsourcing can include automation | Researchers use AI to identify possible COVID-19 treatments
August 18, 2020
ISPE SmartBrief
Connecting Pharmaceutical KnowledgeSIGN UP ⋅   SHARE
Process development and manufacturing
Process validation is essential for the manufacturing of advanced medical therapies, but inherent limitations contribute to variation and uncertainty in industry and regulatory approaches to development, approval and launch of new products, writes Mark Witcher. He outlines ways process validation concepts can be modified to better manage the next generations of biopharmaceuticals.
Full Story: Pharmaceutical Online (8/14) 
LinkedIn Twitter Facebook Email
Facilities and equipment
Functional service providers save pharmaceutical manufacturers money by providing staffing solutions, but companies should look at FSPs for technology that can save time as well, writes Michael Jones, vice president of clinical FSP client engagement for IQVIA. "A clinical research organization partner capable of providing a centralized solution with real-time data analytics and AI/ML-enabled workflows can help study teams more efficiently improve data quality, ensure site compliance, and stay on top of patient and site risk management," Jones writes.
Full Story: Contract Pharma (8/17) 
LinkedIn Twitter Facebook Email
Information systems
Researchers at the University of California at Riverside are using a machine learning tool to create a database of compounds that could be used to develop COVID-19 treatments. The technology identifies any potential toxicity and FDA-approved compounds.
Full Story: Genetic Engineering & Biotechnology News (8/13) 
LinkedIn Twitter Facebook Email
Supply chain management
The European Commission and AstraZeneca have finalized a vaccine deal that involves the acquisition of a minimum of 300 million doses of the company's COVID-19 vaccine, including an option for an additional purchase of 100 million more doses.
Full Story: CNBC/Reuters (8/14) 
LinkedIn Twitter Facebook Email
Novavax announced Friday that it received an order of 60 million doses for NVX-CoV2373, its coronavirus vaccine candidate, from the UK. A late-stage trial will be launched by the UK government and the company that will include about 9,000 adults in the UK.
Full Story: Reuters (8/14) 
LinkedIn Twitter Facebook Email
Quality and regulatory issues
FDA finalizes penalties for trial reporting violations
The FDA has released final guidance detailing the civil monetary penalties for companies that violate federal regulations requiring the complete and accurate registration of clinical studies and results reporting on clinicaltrials.gov. The statutory minima for penalties are up to $10,000 for all violations adjudicated in a single proceeding and up to $10,000 per day after notification that a violation remains uncorrected.
Full Story: Regulatory Focus (8/14) 
LinkedIn Twitter Facebook Email
Research and development
Thermo Fisher, Hengrui Therapeutics team on lung cancer CDx
Thermo Fisher Scientific is partnering with Jiangsu Hengrui Medicine's subsidiary Hengrui Therapeutics to advance development of a companion diagnostic test that can identify lung cancer patients with HER2 mutations who are eligible to use Jiangsu Hengrui Medicine's pyrotinib.
Full Story: GenomeWeb Daily News (free registration) (8/17) 
LinkedIn Twitter Facebook Email
Pluristem Therapeutics and the Abu Dhabi Stem Cells Center based in the United Arab Emirates signed a nonbinding memorandum of understanding with the aim of developing regenerative medicines and cell therapies to treat severe diseases, including COVID-19. No financial details were disclosed.
Full Story: Seeking Alpha (free registration) (8/17) 
LinkedIn Twitter Facebook Email
ISPE update
Although travel continues to be reduced or restricted worldwide, there is an upside: The 2020 ISPE Asia Pacific Pharmaceutical Manufacturing Virtual Conference & Executive Forum has now pivoted into a fully virtual event providing attendees located anywhere in the world with real-time engagement with Regulatory and Industry leaders. Full Story: iSpeak Blog
LinkedIn Twitter Facebook Email
ISPE announced its 2020 ISPE Europe Annual Conference, taking place virtually Sept. 15-16, 2020, will feature a diverse mix of global health authorities providing insights on COVID-19. Twenty regulatory experts representing 10 countries will share perspectives and lessons learned on the pandemic impacting drug shortages, distant assessments, and good manufacturing practices reliance. Full Story: ISPE News
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT ISPE:
ISPE  |    Conferences  |    ISPE Learning Solutions  |    Membership  |    Guidance Documents  |    PE Magazine
Sharing ISPE SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/ispe/?referrerId=hMrCuMGh
An idea starts to be interesting when you get scared of taking it to its logical conclusion.
Nassim Nicholas Taleb,
essayist, scholar, mathematical statistician, risk analyst
LinkedIn Twitter Facebook Email
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004